The Inflammation Research Center (IRC) was born on January 1, 2014 following the active collaboration of the three research units. CRB3-U773, U843 and UMRS 699.

First Europpen Research Center specialized in the study of inflammatory mechanisms. This joint research unit (INSERM, CNRS, University of Paris) federates the forces of 12 teams of fundamental and clinical research on the subject of the inflammation of the liver, the kidney, the pancreas, the intestine, and the immune system .

Today, the IRC brings together more than 250 researchers, engineers and administrators spread over two sites (Bichat and Beaujon) and collaborates with 4 hospitals, Bichat, Beaujon, Robert Debré and Louis Mourier.

The IRC is a major player in the laboratory of excellence “Institute of Inflammatory Diseases” (Inflamex) coordinated by R. Monteiro, DHU Unity (led by D.Valla) and DHU Fire (co-coordinated by B. Crestani, G Steg & E. Daugas)

The goal of the 12 teams that make up the IRC is to establish a “Center of Excellence” that links basic research with translational and clinical research in inflammatory diseases and ensures an optimal approach to the patient.

“We strive to find the right balance between basic research and clinical research – our approach is from the bench to the bedside.”

Pr Renato Monteiro, Director

Science Policy:

  • Promote and facilitate active collaboration between scientists and clinicians in inflammation research
  • Promote the emergence of new projects and research teams in the field of inflammatory mechanisms
  • Contribute to the training of young researchers
  • Establish strengthened, academic or industrial partnerships that support the application of research results
  • Participate in the international influence of France by conducting a high quality research

The scientific objectives of the CRI:

  • Understand fundamentally the basics of inflammatory processes and the development of fibrosis
  • Identify new pathophysiological mechanisms of inflammatory diseases, biomarkers associated with diseases and develop new imaging tools
  • Create new preclinical animal models for proof of concept (POC) for the study of inflammatory diseases
  • Seek new therapeutic approaches.